Team:Tsinghua/Introduction

From 2014.igem.org

(Difference between revisions)
Line 70: Line 70:
<section>
<section>
<h2>Abstract</h2>
<h2>Abstract</h2>
-
<p>&nbsp;&nbsp;&nbsp;&nbsp;<i><b> Type I diabetes mellitus <b><i> (T1DM) affects more than 17 million people worldwide, and current treatments for T1DM, known as insulin therapy, require continued insulin injection, diet control, and constant monitoring of blood sugar. Gene therapy methods that restore insulin production in non-pancreatic cells might provide a one-shot cure for T1DB. We propose a gene therapy for T1DM using an adeno-associated viral (AAV) vector that transfects somatic cells with an insulin gene controlled by a glucose-sensitive promoter, thus potentially restoring glucose-regulated insulin production in diabetic patients. Preliminary tests are conducted on cell lines to assess the efficiency of the therapy.</p>
+
<p>&nbsp;&nbsp;&nbsp;&nbsp;<i><b> Type I diabetes mellitus </b></i> (T1DM) affects more than 17 million people worldwide, and current treatments for T1DM, known as insulin therapy, require continued insulin injection, diet control, and constant monitoring of blood sugar. Gene therapy methods that restore insulin production in non-pancreatic cells might provide a one-shot cure for T1DB. We propose a gene therapy for T1DM using an adeno-associated viral (AAV) vector that transfects somatic cells with an insulin gene controlled by a glucose-sensitive promoter, thus potentially restoring glucose-regulated insulin production in diabetic patients. Preliminary tests are conducted on cell lines to assess the efficiency of the therapy.</p>
</section>
</section>
<section><p>&nbsp;</p></section>
<section><p>&nbsp;</p></section>

Revision as of 16:23, 17 October 2014

Team Tsinghua 2014 Return to iGEM 2014

Introduction: Overview

Abstract

     Type I diabetes mellitus (T1DM) affects more than 17 million people worldwide, and current treatments for T1DM, known as insulin therapy, require continued insulin injection, diet control, and constant monitoring of blood sugar. Gene therapy methods that restore insulin production in non-pancreatic cells might provide a one-shot cure for T1DB. We propose a gene therapy for T1DM using an adeno-associated viral (AAV) vector that transfects somatic cells with an insulin gene controlled by a glucose-sensitive promoter, thus potentially restoring glucose-regulated insulin production in diabetic patients. Preliminary tests are conducted on cell lines to assess the efficiency of the therapy.

 

Background

Retrieved from "http://2014.igem.org/Team:Tsinghua/Introduction"